A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

Last updated: June 21, 2011
Sponsor: Bristol-Myers Squibb
Overall Status: Completed

Phase

3

Condition

Multiple Myeloma

Cancer/tumors

Platelet Disorders

Treatment

N/A

Clinical Study ID

NCT00546780
CA200-004
KAG-301
  • Ages > 18
  • All Genders

Study Summary

This is a phase 3, open label trial for patients with multiple myeloma in first relapse. Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of bortezomib versus bortezomib alone.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Good Performance Status

  • Documented evidence of multiple myeloma

  • Documented progression of disease after initial response to one line of therapy

  • Measurable disease (serum M-protein >.5g/dl or > 200 mg urinary M protein excretion)

Exclusion

Exclusion Criteria:

  • Prior treatment with a heat shock 90 inhibitor or an investigational proteasomeinhibitor

  • Known active infections of HAV, HBV, HCV, or HIV

  • Administration of chemotherapy, radiation therapy, or immune therapy within 21 daysprior to randomization.

  • Acute diffuse infiltrate pulmonary disease or pericardial dise

Study Design

Total Participants: 31
Study Start date:
February 01, 2008
Estimated Completion Date:
March 31, 2010

Study Description

Phase 3 combination study comparing tanespimycin (KOS-953) plus bortezomib to bortezomib alone in patients with multiple myeloma in first relapse after failure of previous anti-cancer therapy and/or bone marrow transplantation. Primary objective is to compare the progression-free survival (PFS) associated with the use of tanespimycin (KOS-953) in combination with bortezomib versus that associated with administration of bortezomib alone.

Connect with a study center

  • Local Institution

    Edmonton, Alberta T6G 1Z2
    Canada

    Site Not Available

  • Comprehensive Blood And Cancer Center

    Bakersfield, California 93309
    United States

    Site Not Available

  • Moores Ucsd Cancer Center

    La Jolla, California 92093
    United States

    Site Not Available

  • University Of California Medical Center

    San Francisco, California 94143
    United States

    Site Not Available

  • Rocky Mountain Cancer Centers

    Denver, Colorado 80218
    United States

    Site Not Available

  • University Of Iowa Hospitals And Clinics

    Iowa City, Iowa 52242
    United States

    Site Not Available

  • University Of Kansas Medical Center

    Westwood, Kansas 66205
    United States

    Site Not Available

  • Dana-Farber Cancer Institute

    Boston, Massachusetts 02215
    United States

    Site Not Available

  • Henry Ford Health System Irb

    Detroit, Michigan 48202
    United States

    Site Not Available

  • Capitol Comprehensive Cancer Care Center

    Jefferson City, Missouri 65109
    United States

    Site Not Available

  • Columbia University Medical Center (Cumc)

    New York, New York 10032
    United States

    Site Not Available

  • Wake Forest Univ Health Sciences

    Winston-Salem, North Carolina 27157
    United States

    Site Not Available

  • Kaiser Permanente Oncology/Hematology

    Portland, Oregon 97227
    United States

    Site Not Available

  • Thomas Jefferson University

    Philadelphia, Pennsylvania 19107
    United States

    Site Not Available

  • Tennessee Cancer Specialists

    Knoxville, Tennessee 37920
    United States

    Site Not Available

  • Sarah Cannon Research Institute

    Nashville, Tennessee 37203
    United States

    Site Not Available

  • Baylor University Medical Center

    Dallas, Texas 75246
    United States

    Site Not Available

  • University Of Virginia Health System

    Charlottesville, Virginia 22908
    United States

    Site Not Available

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin 53226
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.